Cite

HARVARD Citation

    Morita, A. et al. (2021). Long‐term analysis of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa: Open‐label phase 3 results. Journal of dermatology. 48 (1), pp. 3-13. [Online]. 
  
Back to record